Showing results 1 - 10 of 21
At GJE our specialist and highly experienced biotech patent attorneys have a deep understanding of the commercial realities of the sector. We appreciate the strategic value of IP to a biotech company...
With London Life Sciences Week starting on 15 November, we’re sharing our top ten practical tips for building a stronger, smarter IP strategy....
Director Lucy Samuels from our Chemistry and life sciences team will be moderating the panel discussion ‘’Claim interpretation, description conflicts, and the next chapter in life sciences after G...
GJE is pleased to announce that the firm has formed an alliance with the German patent and trade mark firm Wächtershäuser & Hartz (W&H)...
Thursday 14 March 2024 I 6:00 pm (London UK – GMT) GJE look forward to hosting the next Biotech Buddies networking event at our office in Broadgate Tower. Several members of our chemistry and life s...
On 21 March, Imago BioSciences, Inc., a clinical-stage biotechnology company developing innovative treatments for myeloid diseases, announced a $40 million Series B financing led by Omega Funds, a GJE...
In our latest article, we explore the boundaries of the experimental use exemption, when research activities may still create infringement risks, and what this means for biotech companies as their R&D...
Join Ross Cummings who will be speaking in the session ‘‘Patent strategy for RNA therapeutics in Europe and US” on Thursday 23 July at 9:10....
GJE welcomes Denise Nestle-Nguyen who has joined our chemistry and life sciences team as a senior associate...
Join us at the Bio Integrates conference on 14 May 2026 which will explore how biotech companies can thrive in an evolving landscape....